首页> 外文期刊>Journal of the American Society for Mass Spectrometry >HAMS: High-Affinity Mass Spectrometry Screening. A High-Throughput Screening Method for Identifying the Tightest-Binding Lead Compounds for Target Proteins with No False Positive Identifications
【24h】

HAMS: High-Affinity Mass Spectrometry Screening. A High-Throughput Screening Method for Identifying the Tightest-Binding Lead Compounds for Target Proteins with No False Positive Identifications

机译:HAMS:高亲和力质谱筛查。一种高通量筛选方法,用于鉴定目标蛋白的最紧密结合的前导化合物,而没有错误的阳性鉴定

获取原文
获取原文并翻译 | 示例
           

摘要

A major challenge in drug discovery is the identification of high affinity lead compounds that bind a particular target protein; these leads are typically identified by high throughput screens. Mass spectrometry has become a detection method of choice in drug screening assays because the target and the ligand need not be modified. Label-free assays are advantageous because they can be developed more rapidly than assays requiring labels, and they eliminate the risk of the label interfering with the binding event. However, in commonly used MS-based screening methods, detection of false positives is a major challenge. Here, we describe a detection strategy designed to eliminate false positives. In this approach, the protein and the ligands are incubated together, and the non-binders are separated for detection. Hits (protein binders) are not detectable by MS after incubation with the protein, but readily identifiable by MS when the target protein is not present in the incubation media. The assay was demonstrated using three different proteins and hundreds of non-inhibitors; no false positive hits were identified in any experiment. The assay can be tuned to select for ligands of a particular binding affinity by varying the quantity of protein used and the immobilization method. As examples, the method selectively detected inhibitors that have K-i values of 0.2 mu M, 50 pM, and 700 pM. These findings demonstrate that the approach described here compares favorably with traditional MS-based screening methods.
机译:药物发现中的主要挑战是鉴定结合特定靶蛋白的高亲和力先导化合物。这些线索通常通过高通量筛选来识别。质谱法已成为药物筛选测定中选择的一种检测方法,因为目标和配体不需要进行修饰。无标记的测定法是有利的,因为它们可以比需要标记的测定法更快地发展,并且它们消除了标记物干扰结合事件的风险。但是,在常用的基于MS的筛查方法中,假阳性的检测是一项重大挑战。在这里,我们描述了一种旨在消除误报的检测策略。在这种方法中,将蛋白质和配体一起孵育,并分离非结合剂以进行检测。与蛋白质一起孵育后,MS无法检测到命中(蛋白质结合物),但当孵育培养基中不存在目标蛋白质时,则可以通过MS轻松识别。使用三种不同的蛋白质和数百种非抑制剂证明了该检测方法的有效性。在任何实验中均未发现假阳性结果。通过改变蛋白质的使用量和固定方法,可以调整检测方法以选择具有特定结合亲和力的配体。作为例子,该方法选择性地检测了具有0.2μM,50pM和700pM的K-i值的抑制剂。这些发现表明,此处描述的方法与传统的基于MS的筛查方法相比具有优势。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号